Kurtoglu Metin 4

Accession 0001453687-24-000140

CIK 0001453687other

Filed

Nov 20, 7:00 PM ET

Accepted

Nov 21, 6:52 PM ET

Size

20.6 KB

Accession

0001453687-24-000140

Form 4

Period: 2024-11-19

Chief Technology Officer

Transactions

Sale
Common Stock
2024-11-20$18.09/sh−100$1,809→ 51,033 total
Sale
Common Stock
2024-11-19$19.50/sh−200$3,900→ 51,033 total
Exercise/Conversion
Common Stock
2024-11-20$1.41/sh+5,700$8,037→ 56,733 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-11-20−5,700→ 125,552 total
Exercise: $1.41Exp: 2026-11-06→ Common Stock (5,700 underlying)
Exercise/Conversion
Common Stock
2024-11-19$1.41/sh+200$282→ 51,233 total
Sale
Common Stock
2024-11-20$17.28/sh−5,600$96,761→ 51,133 total
Sale
Common Stock
2024-11-21$16.67/sh−32,789$546,560→ 51,033 total
Exercise/Conversion
Common Stock
2024-11-21$1.41/sh+32,789$46,232→ 83,822 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-11-19−200→ 131,252 total
Exercise: $1.41Exp: 2026-11-06→ Common Stock (200 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-11-21−32,789→ 92,763 total
Exercise: $1.41Exp: 2026-11-06→ Common Stock (32,789 underlying)

Footnotes (4)

[F1]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.01 to $17.98. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F2]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.50 to $17.42. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The option was fully vested and exercisable upon the closing of the merger described in footnote 4.
[F4]On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

Documents

1 file

Cartesian Therapeutics, Inc.

CIK 0001453687

Entity typeother